Austin Pain Associates Physicians: A Testing Protocol Built Around Revenue

In the Austin Pain Associates urine testing settlement, two former physician co-owners agreed to pay $3.9 million over allegations of medically unnecessary urine drug testing billed to Medicare, Medicaid and TRICARE. The government alleged that the physicians wrote the testing protocols, knew their in-house laboratory was running excessive tests, and depended on that unnecessary testing to keep the practice profitable. For someone who worked inside the clinic, the question was what drove the next order: the patient’s condition or the practice’s need for another test.

The Department of Justice announced the settlements on October 22, 2021. Austin Pain Associates was an Austin, Texas pain-management practice that had closed by the announcement. Two former employees brought the whistleblower case. Their complaint describes how testing changed inside the practice, down to the risk assessments, the collection cups and the pressure to order more. The alleged scheme put the cost on taxpayer-funded health care programs and sent patients back for more samples.

What Austin Pain Allegedly Ordered

The government alleged that the physicians caused false claims by ordering excessive urine drug testing without assessing each patient’s clinical need. Its announcement describes all urine drug tests ordered by the practice’s physicians going to its in-house laboratory starting in 2011.

The employees’ complaint gives a closer account of the change in testing. It alleges that the practice initially used point-of-care cup tests for new and existing patients, without automatically sending every sample for more detailed analysis. After acquiring a laboratory, the practice allegedly expanded its use of LC/MS testing, then abandoned the cup tests for new patients and eventually for everyone. The more expensive laboratory analysis became the routine test.

The whistleblowers alleged that frequency increased too. Some patients underwent LC/MS testing every two or three days, others weekly, and others every two weeks. The complaint also described a revised decision tree that started all patients at a moderate monitoring level and prevented them from moving to low monitoring during their first six months of treatment.

The alleged protocol made repeated testing the starting point. The individual patient’s history then had to fit inside it.

A Risk Label That Produced More Testing

The complaint alleged that Austin Pain’s risk classifications pushed patients toward more testing even when the reason for the label had little to do with their own behavior. One employee challenged a rule under which a patient could be classified as high risk because a family member had depression, despite the patient having no history of aberrant behavior or diagnosis of psychiatric instability.

Another example concerned a patient who physically could not provide urine as frequently as the practice demanded. The whistleblower alleged:

In that account, difficulty supplying a sample became the reason to demand more samples. A label meant to guide care instead reinforced the testing schedule the patient already could not meet.

When Are Toxicology Tests Unnecessary?

Toxicology tests are unnecessary when they lack a patient-specific clinical reason for the information they produce. In this case, the government alleged that the physicians’ protocols replaced that assessment with excessive testing. The test method, the substances tested and the interval between samples all matter to that question.

The clinical literature explains why the patient’s circumstances belong at the center of the decision. The Journal of Family Practice’s 2021 review, Urine Drug Screening: A Guide to Monitoring Tx With Controlled Substances, recommends a risk-based approach to testing frequency. It describes ongoing assessment using baseline tests, the patient’s account, toxicology results, behavioral monitoring and prescription-monitoring information.

The review also makes a point that gets lost when the laboratory result becomes the whole encounter:

The review recommends revisiting unexpected results with a thorough history or confirmatory testing. In its discussion of testing costs, it identifies large expensive panels, excessive frequency and unnecessary confirmation as practices through which a financial interest in testing can produce abuse.

A 2014 Pain Physician paper, Ethical Perspectives on Urine Drug Screening for Pain Physicians, describes drug testing as a tool to support the relationship between physician and patient. In the complaint’s account, the demands for samples drove a patient away.

The Revenue Pressure Behind the Orders

The whistleblowers alleged that compensation rewarded the medical staff for generating revenue. Their complaint described the incentive in direct terms:

The government alleged that the practice itself could not remain profitable without unnecessary urine testing. The complaint’s compensation account adds another level: the staff making orders could allegedly increase their own income by generating procedures.

Beyond urine testing, the complaint alleged a quota requiring a full hormone panel at least once for every patient, with pressure emails from a physician-owner to practitioners who had not ordered it.

The connection for an insider is the decision inside the practice: who selected the tests, who pressed for more, and how the resulting work affected compensation.

The Physicians’ Separate Settlement Payments

The two former co-owners entered separate settlement agreements. The physician identified in the complaint as the practice’s founder agreed to pay $2.1 million. The other former co-owner agreed to pay $1.8 million.

Texas was to receive approximately $260,000 from the settlements because it had funded part of the Medicaid claims at issue.

The resolution also covered the claims brought by the former employees under the False Claims Act’s whistleblower provisions. The announcement allocated them a share of the federal recovery.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The Same Ordering Problem Beyond an In-House Lab

Precision Toxicology’s $27 million settlement, announced by the Department of Justice in October 2024, involved a similar allegation about the decision that came before the sample reached the laboratory. The government contended that its custom profiles operated as standing orders, causing physicians to request large numbers of urine tests without assessing each patient’s needs.

Austin Pain’s alleged device was its own physicians’ testing protocol. Precision’s was a laboratory’s promotion of custom profiles. Both accounts put the ordering decision at the center of the unnecessary-testing allegation. A form can look tailored to a practice while still replacing the decision about an individual patient.

What an Insider Can Connect

The Austin Pain complaint shows why the protocol’s history can matter alongside the billed tests. It compared earlier and later risk-assessment instructions, described the move away from cup testing, and identified pressure on staff to order procedures. The final claim captures the bill. Those earlier decisions explain how the bill came to exist.

You Saw What Drove the Next Order

If you saw a testing protocol change to serve the practice’s revenue, talk with our whistleblower experts about what happened inside the clinic. We build the case with you and bring in healthcare whistleblower lawyers who understand laboratory billing and pain-management testing. We stay beside you as partners through the case, connecting your account of the ordering pressure to the billed tests to build your strongest laboratory fraud whistleblower case.